Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

Kennedy is vowing to "fix" the federal program for compensating Americans injured by vaccines, opening the door to sweeping ...

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower second-quarter results due to persistently weak demand for its Gardasil vaccine in ...

Merck’s MRK second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV). Though the vaccine’s sales rose consistently till ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of ...

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China. Shares of Merck ...

Merck's Gardasil sales fell short of expectations in the fourth quarter, and the company pulled its long-term target of $11 billion in Gardasil sales by 2030 in light of the decision to stop shipments ...

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil shipment pause in China and forex impact.

Merck said it had stopped Gardasil shipments to China from this month. The company has previously said China's anti-bribery and anti-corruption drive had also hurt sales of the vaccine.

Merck reported a decline of 17% in sales of Gardasil to $1.55 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., primarily due to lower ...

"The approval of GARDASIL for use in males 9-26 years old in China is a significant step forward in advancing public health," said Joseph Romanelli, president, Human Health International, Merck.